A new analysis from the REDUCE-IT trial has shown that the high-strength eicosapentaenoic acid product icosapent ethyl (Vascepa, Amarin) reduced the number of revascularization procedures by approximately one third in statin-treated patients whose triglyceride levels were elevated and who were at increased cardiovascular risk.
The new data were presented at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 meeting.
